Recent Publications

  1. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia.
    Krugliak Cleveland N, Ollech JE, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Hurst R, Rubin DT.
    Clin Gastroenterol Hepatol. 2019 Jan;17(1):205-206. doi: 10.1016/j.cgh.2018.04.061. Epub 2018 May 8.
    PMID: 29751167

  2. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies.
    Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A.
    J Clin Gastroenterol. 2019 Jan;53(1):e1-e11. doi: 10.1097/MCG.0000000000000865.
    PMID: 28737645

  3. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.
    J Crohns Colitis. 2019 Jan 1;13(1):139-140. doi: 10.1093/ecco-jcc/jjy135.
    PMID: 30412228

  4. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
    Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT.
    J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi: 10.1093/ecco-jcc/jjy125.
    PMID: 30203005

  5. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study.
    Melmed GY, Dubinsky MC, Rubin DT, Fleisher M, Pasha SF, Sakuraba A, Tiongco F, Shafran I, Fernandez-Urien I, Rosa B, Papageorgiou NP, Leighton JA.
    Gastrointest Endosc. 2018 Dec;88(6):947-955.e2. doi: 10.1016/j.gie.2018.07.035. Epub 2018 Aug 4.
    PMID: 30086261

  6. Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients.
    Sossenheimer PH, Glick LR, Dachman A, Skowron KB, Rubin M, Umanskiy K, Smith R, Cannon L, Hurst RD, Cohen RD, Hyman NH, Rubin DT.
    Dis Colon Rectum. 2018 Nov 2018 Nov 28. doi: 10.1097/DCR.0000000000001285. [Epub ahead of print]
    PMID: 30540661

  7. Emerging Therapies for Inflammatory Bowel Disease.
    Weisshof R, El Jurdi K, Zmeter N, Rubin DT.
    Adv Ther. 2018 Nov;35(11):1746-1762. doi: 10.1007/s12325-018-0795-9. Epub 2018 Oct 29. Review.
    PMID: 30374806

  8. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease.
    Anyane-Yeboa A, Yamada A, Haider H, Wang Y, Komaki Y, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.
    Aliment Pharmacol Ther. 2018 Nov;48(9):933-940. doi: 10.1111/apt.14951. Epub 2018 Aug 20.
    PMID: 30126019

  9. The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn's and Colitis Foundation.
    Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, Buchanan S, Zmeter N, Rubin DT.
    Inflamm Bowel Dis. 2018 Oct 24. doi: 10.1093/ibd/izy319. [Epub ahead of print]
    PMID: 30358848

  10. Discussion of Code Status in the Peri-Endoscopic Period.
    Rao VL, Feld LD, Rubin DT.
    Am J Gastroenterol. 2018 Oct 17. doi: 10.1038/s41395-018-0370-7. [Epub ahead of print]
    PMID: 30333550

  11. Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis.
    Colman RJ, Lawton RC, Dubinsky MC, Rubin DT.
    Inflamm Bowel Dis. 2018 Sep 15;24(10):2135-2141. doi: 10.1093/ibd/izy078.
    PMID:29688409

  12. Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease.
    Raffals LE, Nguyen GC, Rubin DT.
    Clin Gastroenterol Hepatol. 2018 Sep 7. pii: S1542-3565(18)30943-1. doi: 10.1016/j.cgh.2018.08.064. [Epub ahead of print]
    PMID: 30196164

  13. Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion.
    Wang J, Bhatia A, Krugliak Cleveland N, Gupta N, Dalal S, Rubin DT, Sakuraba A.
    ACG Case Rep J. 2018 Aug 1;5:e56. doi: 10.14309/crj.2018.56. eCollection 2018.
    PMID: 30105273

  14. The use of tofacitinib in the treatment of inflammatory bowel disease.
    Weisshof R, Golan MA, Yvellez OV, Rubin DT.
    Immunotherapy. 2018 Aug;10(10):837-849. doi: 10.2217/imt-2018-0015. Epub 2018 Apr 27.
    PMID:29701124

  15. Legal Risks and Considerations Associated with Inflammatory Bowel Disease: A Primer.
    Feld LD, Rubin DT, Feld AD.
    Am J Gastroenterol. 2018 Jul 16. doi: 10.1038/s41395-018-0204-7. [Epub ahead of print]
    PMID: 30008471

  16. Identification of Endpoints for Development of Anti-fibrosis Drugs for Treatment of Crohn's Disease.
    Danese S, Bonovas S, Lopez A, Fiorino G, Sanborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L.
    Gastroenterology. 2018 Jul;155(1):76-87. doi: 10.1053/j.gastro.2018.03.032. Epub 2018 Mar 28. Review.
    PMID:29601825

  17. Enteric infections complicating ulcerative colitis.
    Micic D, Hirsch A, Setia N, Rubin DT.
    Intest Res. 2018 Jul;16(3):489-493. doi: 10.5217/ir.2018.16.3.489. Epub 2018 Jul 27.
    PMID: 30090049

  18. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
    Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT.
    J Clin Gastroenterol. 2018 Jul;52(6):537-544. doi: 10.1097/MCG.0000000000000889.
    PMID: 28723860

  19. The New Frontier: the Intestinal Microbiome and Surgery.
    Skowron KB, Shogan BD, Rubin DT, Hyman NH.
    J Gastrointest Surg. 2018 Jul;22(7):1277-1285. doi: 10.1007/s11605-018-3744-7. Epub 2018 Apr 9.
    PMID:29633119

  20. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.
    Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J.
    Inflamm Bowel Dis. 2018 May 18;24(6):1291-1297. doi: 10.1093/ibd/izx105.
    PMID:29506124

  21. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
    Christensen B, Gibson P, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT.
    Clin Gastroenterol Hepatol. 2018 May 8. pii: S1542-3565(18)30466-X. doi: 10.1016/j.cgh.2018.04.060. [Epub ahead of print]
    PMID:29751166

  22. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY, Buisson A, Andersen MJ Jr, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT.
    Dig Dis Sci. 2018 May;63(5):1294-1301. doi: 10.1007/s10620-018-4980-0. Epub 2018 Feb 22.
    PMID:29468374

  23. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease.
    Krugliak Cleveland N, Huo D, Sadiq F, Sofia MA, Marks J, Cohen RD, Hanauer SB, Turner J, Hart J, Rubin DT.
    Gastrointest Endosc. 2018 May;87(5):1304-1309. doi: 10.1016/j.gie.2017.12.016. Epub 2018 Jan 4.
    PMID: 29307473

  24. Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey.
    Yarlas A, Rubin DT, Panés J, Lindsay JO, Vermeire S, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, DiBonaventura M.
    J Crohns Colitis. 2018 Apr 27;12(5):600-609. doi: 10.1093/ecco-jcc/jjy024.
    PMID:29718244

  25. Efficacy of vedolizumab in fistulising Crohn's disease: Exploratory analyses of data from GEMINI 2.
    Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K.
    J Crohns Colitis. 2018 Apr 27;12(5):621-626. doi: 10.1093/ecco-jcc/jjy019.
    PMID:29471381

  26. Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis.
    Pekow J, Meckel K, Dougherty U, Haider HI, Deng Z, Hart J, Rubin DT, Bissonnette M.
    Oncotarget. 2018 Apr 17;9(29):20709-20720. doi: 10.18632/oncotarget.25065. eCollection 2018 Apr 17.
    PMID:29755683

  27. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.
    Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT.
    Dig Dis Sci. 2018 Apr;63(4):1016-1024. doi: 10.1007/s10620-018-4941-7. Epub 2018 Feb 8.
    PMID: 29417331

  28. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
    Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.
    Inflamm Bowel Dis. 2018 Mar 19;24(4):849-860. doi: 10.1093/ibd/izx067.
    PMID:29562271

  29. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT.
    Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29.
    PMID: 29377235

  30. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
    Yamada A, Komaki Y, Patel N, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.
    Inflamm Bowel Dis. 2018 Feb 15;24(3):502-509. doi: 10.1093/ibd/izx054. PMID: 29462385

  31. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.
    J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133.
    PMID: 29028981

  32. Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon.
    Cleveland NK, Rubin DT, Hart J, Weber CR, Meckel K, Tran AL, Aelvoet AS, Pan I, Gonsalves A, Gaetano JN, Williams K, Wroblewski K, Jabri B, Pekow J.
    Clin Gastroenterol Hepatol. 2018 Jan;16(1):68-74. doi: 10.1016/j.cgh.2017.07.023. Epub 2017 Jul 26.
    PMID:28756053

  33. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Gibofsky A, Skup M, Mittal M, Johnson SJ, Davis M, Chao J, Rubin DT.
    Curr Med Res Opin. 2017 Nov;33(11):1945-1953. doi: 10.1080/03007995.2017.1375903. Epub 2017 Sep 21.
    PMID: 28870101

  34. Recent Research on Joint Pain and Arthritis in Patients With Inflammatory Bowel Disease.
    Rubin DT
    .
    Gastroenterol Hepatol (N Y). 2017 Nov;13(11):688-690.
    PMID: 29230148

  35. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease.
    Micic D, Gaetano JN, Rubin JN, Cohen RD, Sakuraba A, Rubin DT, Pekow J.
    PLoS One. 2017 Aug 24;12(8):e0182900. doi: 10.1371/journal.pone.0182900. eCollection 2017.
    PMID: 28837634

  36. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.
    Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT.
    Clin Gastroenterol Hepatol. 2017 Oct;15(10):1557-1564.e1. doi: 10.1016/j.cgh.2017.02.016. Epub 2017 Feb 24.
    PMID: 28238954 

  37. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, Castaño-Rodríguez N.
    J Crohns Colitis. 2017 May 9. doi: 10.1093/ecco-jcc/jjx063. [Epub ahead of print]
    PMID: 28486648

  38. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.
    Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.
    Am J Gastroenterol. 2017 Jul 18. doi: 10.1038/ajg.2017.201. [Epub ahead of print]
    PMID:28719595

  39. miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD.
    Pekow J, Meckel K, Dougherty U, Huang Y, Chen X, Almoghrabi A, Mustafi R, Ayaloglu-Butun F, Deng Z, Haider HI, Hart J, Rubin DT, Kwon JH, Bissonnette M.
    Clin Cancer Res. 2017 Jun 9. doi: 10.1158/1078-0432.CCR-17-0171. [Epub ahead of print]
    PMID: 28600480

  40. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.
    J Manag Care Spec Pharm. 2017 Aug;23(8):859-867. doi: 10.18553/jmcp.2017.16272. Epub 2017 Mar 15.
    PMID:28737994

More articles by Dr. Rubin are available on PubMed.gov.